We develop advanced, reliable solutions that harness AI to detect cancer earlier and improve patient care.
Developed through French research and protected by 5 patents, VisioCyt® uses deep-learning and computer-vision algorithms to analyse digitised cytology slides and support diagnosis.
VisioCyt® Bladder is a non-invasive test for the diagnosis and surveillance of bladder cancer using a simple urine sample.
Currently in development, VisioCyt® Screening is designed to screen asymptomatic patients at high risk of bladder cancer.
Currently in development, VisioCyt® Thyroid is designed to support the diagnosis of thyroid cancer.
